
An experimental weight-loss drug developed by REGENERON PHARMACEUTICALS combined with NOVO NORDISK A/S-B's semaglutide cut muscle mass loss by 50% in a study of nearly 1,000 obesity patients.
Regeneron reported its experimental drug trevogrumab halved muscle mass loss when combined with Novo Nordisk weight loss treatment semaglutide in an obesity trial. The combination preserved lean mass effectively, addressing key concerns over muscle degradation during rapid weight loss.

An experimental weight-loss drug developed by REGENERON PHARMACEUTICALS combined with NOVO NORDISK A/S-B's semaglutide cut muscle mass loss by 50% in a study of nearly 1,000 obesity patients.
Everything you use on the web — faster, and in your pocket.